Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. (FHTX) priced its initial public offering on Oct 23, 2020 at $16.00 per share, within its $15.00–$17.00 range, raising $120M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $571.1M. Ropes & Gray advised the company and Latham & Watkins advised the underwriters.

Foghorn Therapeutics Inc. is a company developing medicines that target genetically determined dependencies within the chromatin regulatory system, which controls gene expression. Its proprietary Gene Traffic Control platform is used to identify, validate and potentially drug targets in that system.

Status

IPO

Ticker

FHTX

Exchange

Nasdaq Global Market

Priced

Oct 23, 2020

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$120M

Market cap at IPO price

$571.1M

First filed

Oct 2, 2020

Company counsel

Ropes & Gray

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.